Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $340.00 Price Target at Stifel Nicolaus

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) had its price objective raised by Stifel Nicolaus from $300.00 to $340.00 in a research report sent to investors on Tuesday morning, The Fly reports. Several other research firms also recently issued reports on VRTX. HC Wainwright lifted their price objective on Vertex Pharmaceuticals from $326.00 to $380.00 in […]

Related Keywords

Ourania Tatsis ,Robertw Baird ,Stifel Nicolaus ,Sanfordc Bernstein ,Sangeetan Bhatia ,Vanguard Group Inc ,Vertex Pharmaceuticals Company Profile ,Insider Activity At Vertex Pharmaceuticals ,Vertex Pharmaceuticals Inc ,Canaccord Genuity Group ,Analyst Recommendations For Vertex Pharmaceuticals ,Securities Exchange Commission ,Nasdaq ,Vertex Pharmaceuticals ,Blackrock Inc ,Vertex Pharmaceuticals Stock Performance ,Geode Capital Management ,Pricet Rowe Associates Inc ,Institutional Trading Of Vertex Pharmaceuticals ,News Ratings For Vertex Pharmaceuticals Daily ,Get Rating ,Moderate Buy ,Exchange Commission ,Director Sangeeta ,Street Corp ,Capital Management ,Pricet Rowe Associates ,Vertex Pharmaceuticals Daily ,Nasdaq Vrtx ,Vrtx ,Medical ,92532f10 ,Boost Price Target ,